Reviewed by The Peptide Dispatch Editorial Team · Last reviewed July 6, 2026
Dihexa (DIH) is a cognitive peptide, at the early research stage in the published literature. Synthetic peptide derived from angiotensin IV with extremely potent nootropic effects. Much more potent than BDNF in some assays.
Synthetic peptide derived from angiotensin IV with extremely potent nootropic effects. Much more potent than BDNF in some assays.
| Research Status | Early research |
|---|---|
| Half-Life | Unknown |
| Administration | Oral or subcutaneous |
| Doses Reported in Published Studies | 10-40 mg oral |
HGF/c-Met receptor system activation, promotes synaptogenesis and neuronal growth at picomolar concentrations.
Synthetic peptide derived from angiotensin IV with extremely potent nootropic effects. Much more potent than BDNF in some assays.
HGF/c-Met receptor system activation, promotes synaptogenesis and neuronal growth at picomolar concentrations.
Dihexa is at the following stage in the published literature: Early research. All information is for research and educational purposes only.
Reported half-life: Unknown.
Reported administration route in the literature: Oral or subcutaneous. This is not a recommendation for human use.
Educational content, not medical advice. Effects described are drawn from cited research in study subjects.